Ovid Therapeutics Secures $60M for Pipeline Expansion, Reports Favorable OV329 Data & OV4071 Phase 1 Clearance
summarizeSummary
Ovid Therapeutics announced significant pipeline advancements, including favorable safety and tolerability data for its OV329 program, which will now expand into tuberous sclerosis complex (TSC) seizures and infantile spasms (IS). Additionally, the company received Phase 1 clearance for its OV4071 program, allowing it to initiate clinical trials. To fund these strategic initiatives, Ovid secured a substantial $60 million private placement. This multi-faceted update provides critical capital for accelerating key development programs and de-risks the pipeline for this clinical-stage biopharmaceutical company. Investors will closely watch the progress of the OV329 Phase 2 studies and the OV4071 Phase 1 trial, as well as any further details regarding the private placement's terms.
At the time of this announcement, OVID was trading at $2.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $261.7M. The 52-week trading range was $0.24 to $2.37. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.